91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
In this article from INTELLIGENT health.tech, Andy Coravos, founder of HumanFirst, recently acquired by 91黑料, shares insights on leveraging digital health technologies and wearables to manage chronic conditions. Drawing from her recent Lancet Digital Health review, Coravos highlights the potential of smartwatches and fitness trackers in improving patient outcomes and easing the burden on healthcare systems.
-
Real world data from Symphony Health, an 91黑料 plc company, was used in this retrospective, observational study on prevalence of tendon rupture and tendinopathies among patients with atherosclerotic cardiovascular disease. These results may help healthcare providers to determine the underlying risk of tendon injuries and guide treatment of this patient population.
-
Rare diseases can disproportionately affect minorities, yet these communities are often underrepresented in clinical studies. 91黑料’s experts suggest ways to improve engagement and diversity.
-
In this piece from Clinical Trial Vanguard, Travis Caudill, Vice President, Feasibility, Site Identification & Clinical Informatics explores the improvements in site selection that human-enabled AI is delivering.
-
91黑料 experts, Jack Martin and Simon Bruce share insights with BioSpectrum Asia on emerging trends in obesity treatment and the future implications for pharma.
-
In this article from BIO-IT World, Dr. Chris Smyth, President of 91黑料 Biotech outlines how despite ongoing challenges, biotech companies can build on growing market confidence by utilising their capital in the most effective and efficient way possible, through improved trial designs, timelines and data-responsive strategies.
-
In this article from Applied Clinical Trials, Kelly Corkey, Director, Clinical Supplies Management, IRT and Leonard Wee, VP, Global Supply Chain, Laboratories outline how by adopting a holistic approach that optimises each component of the process, the clinical research industry can collectively drive progress and pivot toward a greener future while continuing to support patient-centred clinical research.
-
In this article, 91黑料 expert, Tim Clark, discuss the shift in paradigms in dose optimisation and dose selection for oncology therapeutics.
-
“ADCs are emerging as one of the fastest-growing segments of pharmaceuticals in 2024, the number of FDA approvals are likely to accelerate, revealing new treatment pathways and new problems to solve along the way.” Learn more in this article with the Clinical Oncologist Daily.
-
This article in the Clinical Oncologist Daily, provides as overview on leveraging healthcare intelligence to increase diversity of oncology clinical trials.
